Insulin Requirement for Gestational Diabetes Control Is Related to Higher Vitamin D Levels up to 1 Year Postpartum: A Prospective Cohort Study.

Vitamin D deficiency is highly prevalent in pregnant women and has been related to a higher risk of gestational diabetes mellitus (GDM). The aim of this study is to analyze vitamin D status evolution in a population of pregnant women with and without GDM. Two-hundred women were included from January 2019 to February 2022 as follows: Control group -CG-, Lifestyle group -LG- (GDM not requiring insulin), and Insulin group -IG- (GDM requiring insulin). Visits were carried out at baseline, antenatal, postpartum, and 1 year after birth. Vitamin D levels, weight, and insulin resistance were measured at every visit. Data about the season, vitamin D supplementation, Mediterranean diet adherence, and physical activity were included. In the three groups, 134 women were included in the CG, 43 in the LG, and 23 in the IG. Vitamin D levels were similar among the groups at baseline, but they were significantly higher in the LG and IG in comparison with the CG at the antenatal visit and significantly higher in the IG vs. CG and LG at the postpartum and 1 year after birth visits. Vitamin D levels were independently related to vitamin D supplementation and the season at baseline, to the season and belonging to the LG or IG at the antenatal visit, and were only independently associated with belonging to the IG at postpartum and 1 year after birth visits. In conclusion, in our population, women with GDM requiring insulin had higher levels of vitamin D in comparison with those not requiring insulin and healthy controls at postpartum and 1 year after pregnancy. Requiring insulin during pregnancy seems to be a factor that independently determines the levels of vitamin D until 1 year after birth. More studies are required to reproduce these data in other populations and to elucidate the mechanisms underlying these findings.

Evaluación de un método POCT (pruebas a la cabecera del paciente) para la determinación de hemoglobina glucosilada / Evaluation of a POCT (point of care testing) assay for haemoglobin A1c

Introducción. La hemoglobina glucosilada (HbA1C) presenta un papel fundamental en el control y prevención de complicaciones en el paciente diabético, puesto que permite la monitorización de sus valores de glucemia en los 3 meses previos al análisis. Introducción. Debido a la importancia de su determinación han aparecido diferentes métodos de cuantificación. El objeto de este trabajo es evaluar el método POCT (point of care testing ‘pruebas a la cabecera del paciente’) mediante el aparato In2it de Bio-Rad. Material y métodos. Se realizó una comparación entre 2 métodos de cuantificación: el HPLC (high–performance liquid chromatography ‘cromatografía líquida de alta resolución o de alta presión’) (ADAMS-A1c HA-8160, Menarini Diagnostics, Florencia, Italia) y el POCT (In2it, Bio-Rad, California, EE.UU.). Para esto, se compararon los resultados de 60 muestras, además de determinar la imprecisión intraserial y la imprecisión interdiaria de ambos aparatos. Resultados. La comparación entre ambos métodos mostró una buena correlación entre el HPLC y el POCT: Y=0,4000+1,000 X. Los intervalos de confianza del 95% para la coordenada en el origen y la pendiente fueron de −0,1500 a 0,6500 y de 0,9565 a 1,0769, respectivamente. Resultados. La imprecisión intraserial se situó entre el 2,5 y el 3% (del 2,20 al 3,04%) y la imprecisión interdiaria se situó entre el 3,53 y el 2,95% para valores altos y bajos, respectivamente. Discusión. El método POCT ha demostrado cumplir todos los requisitos técnicos necesarios para su validación como método para la determinación de la HbA1C, ya que presenta igualdad de prestaciones analíticas con el método HPLC. Además, es apropiado para el seguimiento de pacientes diabéticos en atención primaria, dada su facilidad y sencillez de manejo (AU)

Introduction. The HbA1c is related to the control and prevention of complications in diabetics. This parameter enables glucose control to be monitored in the three months previous to the determination. Introduction. Due to the significance of its determination, different measurement methods have been developed. The aim of this work is to evaluate the POCT (point of care testing) method used by the In2it BioRad. Material and methods. We report on a comparison between two methods: a HPLC (high–performance liquid chromatography) (ADAMS-A1c HA-8160, Menarini) and the POCT test (In2it, BioRad). To determine the within and between day imprecision, 60 samples were analysed and compared. Results. Both methods showed good correlations (Y=0.4000+1.000 X). The 95% confidence intervals for the coordinate at the origin and the slope were (−0.1500 to 0.6500) and (0.9565 to 1.0769), respectively. Within day imprecision was 2.5–3% (2.20–3.04%) and between day imprecision was 3.53% and 2.95% for high and low values, respectively. Discussion. The POCT test (BioRad System) has demonstrated that it fulfils all the technical requirements needed for its validation as an HbA1c analysis method as it has a similar performance to the HPLC method The POCT method has shown to be suitable for the follow-up of diabetic patients in primary care due its ease and simplicity of use (AU)

Evaluación de un método inmunonefelométrico competitivo para la cuantificación de la homocisteína / Evaluation of a competitive immunonephelometric method for the measurement of homocysteine

Introducción y objetivos. La homocisteína se relaciona con enfermedad vascular, alteraciones del estado nutricional y detección de homocistinuria en neonatos, entre otras enfermedades. Debido a la importancia de su determinación, han aparecido diferentes métodos de cuantificación; el objeto de este trabajo es evaluar el método inmunonefelométrico del aparato BN II (Dade Behring). Material y método. Se realizó una comparación entre 2 métodos de cuantificación: el inmunoanálisis competitivo (IMMULITE 2000, DPC) y el análisis nefelométrico (BN II, Dade Behring), para lo cual se compararon los resultados de 74 muestras, además de determinar la imprecisión intraserial, imprecisión interdiaria, el límite de detección, el límite de cuantificación y el valor crítico del método inmunonefelométrico del BN II de Dade Behring. Resultados. La comparación entre ambos métodos mostró una buena correlación entre el inmunoanálisis competitivo, IMMULITE 2000 de DPC y el análisis nefelométrico, BN II de Dade Behring (Y = 1,4825 + 0,8342X). El valor crítico obtenido fue de 5,46 mmol/l y el límite de detección, de 5,77 mmol/l. La imprecisión intraserial fue inferior al 5% (3,65-4,66%). Conclusiones. El análisis nefelométrico (BN II, Dade Behring) ha demostrado cumplir todos los requisitos técnicos necesarios para su validación como método para la determinación de la homocisteína(AU)

Introduction. The homocysteine is associated with vascular diseases, alterations in the nutritional states, homocystinuria detection in neonates, as well as other diseases. Due to the importance of its determination, different measurement methods have been developed. The aim of this work is to evaluate the imunonephelometric method used in the Dade Behring BN II Nephelometer system. Material and method. We present a comparison between 2 methods: a competitive inmunoassay (IMMULITE 2000, DPC) and the nephelometric test (BN II, Dade Behring). For the determination of within batch and between-day imprecision, 74 samples were analysed and compared. Results. The detection and quantification limits, and the critical value of the inmunonephelometric method, were also determined. Both methods showed good correlations (Y = 1.4825 + 0.8342X). We also obtained a critical value of 5.46 mmol/L and the detection limit was 5.77 mmol/L. Within batch imprecision was below 5 % (3.65-4.66%). Conclusions. The nephelometric test (Dade Behring BN II System) has demonstrated to fulfill all the technical requirements needed for its validation as a method for the determination of homocysteine(AU)